

Funder	Project Title	Funding	Institution
Department of Defense - Autism Research Program	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	University of Medicine & Dentistry of New Jersey
Department of Defense - Autism Research Program	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Department of Defense - Autism Research Program	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Autism Speaks	Randomized controlled trial of oxytocin treatment for social deficits in children with autism	\$50,600	Stanford University
Autism Speaks	Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes	\$92,469	Stanford University
Autism Speaks	Randomized phase 2 trial of RAD001 (an mTOR inhibitor) in patients with tuberous sclerosis complex	\$65,000	Boston Children's Hospital
Autism Speaks	A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism	\$0	Holland Bloorview Kids Rehabilitation Hospital
Health Resources and Services Administration	Controlled trial of sertraline in young children with Fragile X Syndrome	\$285,970	University of California, Davis
National Institutes of Health	New experimental medicine studies: Fast-Fail Trials in autism spectrum disorders	\$115,889	University of California, Los Angeles
National Institutes of Health	ACE Center: Augmenting language interventions for ASD: A translational approach	\$281,072	University of California, Los Angeles
National Institutes of Health	Trial of a glutamate antagonist in the treatment of OCD and autistic disorders	\$33,959	National Institutes of Health
National Institutes of Health	ACE Network: Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)	\$2,589,347	University of North Carolina at Chapel Hill
Simons Foundation	Testing the use of helminth worm ova in treating autism spectrum disorders	\$124,802	Montefiore Medical Center
Simons Foundation	Evaluation of a melanocortin agonist to improve social cognition in ASD.	\$74,675	University of Sydney